Question 1

What is allometric scaling in pharmacokinetics?

Accepted Answer

Allometric scaling is a mathematical approach to predicting how pharmacokinetic parameters (clearance, volume of distribution, half-life) change as a function of body size — expressed as a power-law relationship: Y = a × BW^b, where Y is the PK parameter, BW is body weight, and b is the allometric exponent. The term derives from the biological observation that physiological processes scale predictably with body mass across species (interspecies scaling) and across patients of different sizes within a species (intraspecies scaling). The universally applied exponents are: 0.75 for clearance (and other flow-based parameters), 1.0 for volume of distribution, and 0.25 for time-related parameters (half-life). These exponents have empirical support across mammals from mice (0.025 kg) to elephants (5,000 kg) and are the foundation of dose extrapolation from animal toxicology studies to first-in-human dose selection.

Question 2

Why is the allometric exponent for clearance 0.75 and not 1.0?

Accepted Answer

The 0.75 exponent for clearance (and metabolic rate) arises from the fractal geometry of mammalian vascular networks — specifically, the space-filling branching architecture of capillary networks that supply oxygen and nutrients to tissues. West, Brown, and Enquist (1997) derived the 3/4 power scaling from first principles based on the need for vascular networks to minimise transport distances and energy costs across orders-of-magnitude differences in body size. Empirically, hepatic blood flow, GFR, and CYP-mediated metabolic clearance all scale with an exponent close to 0.75 across mammalian species. In clinical practice, this means a 70 kg adult does not have twice the clearance of a 35 kg child — it has 2^0.75 ≈ 1.68 times the clearance. Per-kilogram (mg/kg) dosing in paediatrics overcorrects for clearance — weight-based allometric dosing (mg/kg^0.75) is more accurate for drugs with linear PK.

Question 3

How is allometric scaling used in paediatric pharmacokinetics?

Accepted Answer

In paediatric pharmacokinetics, allometric scaling is combined with maturation functions (MF) to account for both body size differences and ontogeny of drug-metabolising enzymes and renal function. The standard model (Holford et al.) adjusts clearance as: CL = CL_adult × (BW/70)^0.75 × MF, where MF describes CYP enzyme maturation as a sigmoidal function of post-menstrual age (PMA). For renally cleared drugs, GFR maturation reaches adult levels by 8–12 months postnatal age. CYP3A4 and CYP2D6 mature rapidly in neonates to reach and even exceed adult per-kg activity by 1–2 years, then decline proportionally with age. This maturation scaling is built into paediatric PBPK models and population PK analyses used to support FDA PREA and EMA Paediatric Investigation Plan (PIP) dose extrapolations.

Question 4

How is interspecies allometric scaling used in first-in-human dose selection?

Accepted Answer

Interspecies allometric scaling uses animal PK data from multiple species (mouse, rat, dog, monkey) to predict human clearance, volume of distribution, and half-life before first-in-human (FIH) clinical trials. The approach plots log(PK parameter) vs log(body weight) across 3–5 species — if the relationship is linear on a log-log plot, the slope gives the allometric exponent b and the intercept gives coefficient a. Human predictions use BW = 70 kg. For clearance predictions, corrections are often applied: the maximum life span potential (MLP) correction for drugs with time-dependent clearance, or the Wajima unifying exponent approach (exponent 0.73 for CL). Standard allometric scaling typically predicts human CL within 2–3 fold for small-molecule drugs with similar CYP-mediated metabolism across species. PBPK models provide more mechanistic FIH predictions by incorporating species-specific enzyme kinetic data.

Question 5

What are the limitations of allometric scaling?

Accepted Answer

Allometric scaling has several important limitations. First, it assumes that PK processes scale predictably with body weight — this fails for drugs with saturable (nonlinear) kinetics, target-mediated drug disposition (TMDD in biologics), active renal/hepatic secretion mediated by transporters that may not scale allometrically, or enterohepatic circulation. Second, it does not account for species differences in protein binding, metabolic pathways (if a major human CYP2D6 metabolic route is absent in rodents), or receptor expression. Third, for paediatrics, allometric scaling alone without a maturation function significantly underpredicts clearance in neonates and infants (underestimates immaturity). Fourth, simple allometry fails for renally cleared drugs in patients with renal impairment — creatinine clearance must be used. Despite these limitations, allometric scaling remains the foundational tool for dose extrapolation when no human data are available.

PK parameter	Exponent (b)	Physiological basis	Clinical use
Clearance (CL)	0.75	Metabolic/vascular fractal geometry (Kleiber's Law)	FIH dose prediction, paediatric CL extrapolation
Volume of distribution (Vd)	1.0	Proportional to body fluid compartments (lean body water, adipose)	Loading dose extrapolation across body sizes
Half-life (t½)	0.25	Derived: t½ = 0.693×Vd/CL ∝ BW^(1.0−0.75) = BW^0.25	Dosing interval estimation across species
Hepatic blood flow	0.75	Scales with metabolic rate; cardiac output ∝ BW^0.75	High-extraction drug clearance scaling
GFR / renal clearance	0.75	Renal blood flow scales with cardiac output	Renally cleared drug dose extrapolation
Protein binding (fu)	0	Species-specific — does NOT scale allometrically	Must be measured independently per species

Allometric scaling

Standard allometric exponents for PK parameters

Frequently asked questions